Assessment Tool
The journey from discovery to clinical success is challenging in the complex landscape of biopharmaceutical development. One pivotal aspect that can significantly mitigate risks and enhance the probability of success is the implementation of a robust developability assessment tool. This article offers a high-level overview of the importance, process, and advantages of such assessments, as exemplified by Samsung Biologics’ approach.
Investing in Late Discovery/ Early Development?
Investing in late discovery/early development refers to allocating resources toward the evaluation and selection of drug candidates during the later stages of the discovery process and the early stages of development. This strategy aims to mitigate the significant risks associated with clinical development, where a considerable percentage of candidate molecules fail due to various reasons such as safety issues, efficacy concerns, or manufacturing challenges.
During the discovery phase of drug development, researchers identify potential drug candidates that show promise in addressing a specific disease or medical condition. However, not all promising candidates are suitable for further development into marketable drugs. Many factors, including manufacturability, safety profile, and stability, must be carefully assessed to determine a molecule’s development potential.
Conducting a thorough developability assessment at the late discovery phase is crucial to weed out candidates that may pose insurmountable challenges later in development. Samsung Biologics’ assessment tool involves evaluating various physicochemical aspects to pinpoint the most developable molecule. This process can significantly reduce the risk of failure during subsequent development stages by identifying molecules with optimal properties, such as favorable solubility, physical stability, and chemical stability.
Investing resources in late discovery/early development activities allows pharmaceutical companies to make informed decisions about which drug candidates to advance into preclinical and clinical development. Companies can optimize their resource allocation, minimize development costs, and accelerate the timeline to bring new drugs to market by focusing on candidates with the highest likelihood of success.
Key Components of a Developability Assessment
The developability assessment process emerges at a pivotal stage, where the future of potential therapeutics is shaped by a thorough understanding of their intrinsic properties. It is essential to utilize a developability assessment tool early to select the candidate molecule with the most developable properties. Samsung Biologics’ developability assessment tool employs the following criteria for candidate selection:
- Molecular Stability: At the base of the developability assessment process is the molecular stability evaluation. This includes an analysis of the candidate molecule’s resilience to various stressors, such as aggregation propensity, particle formation, chemical degradation, and fragmentation. By scrutinizing the molecule’s behavior under diverse conditions, potential vulnerabilities can be identified early, enabling proactive mitigation strategies.
- Solubility: Another fundamental aspect of developability assessment revolves around assessing the relative solubility of candidate molecules. Solubility plays a pivotal role in determining the molecule’s feasibility for formulation and administration. The relative solubility assay can provide information on a molecule’s solubility in different solution conditions as well as a comparison of different molecules side-by-side. This information guides formulation decisions and influences subsequent activities such as drug delivery. Through comparative analysis, candidates with optimal solubility profiles are identified, setting the stage for streamlined development pathways.
- Low pH Stability: In addition to molecular stability and solubility, low pH stability emerges as a critical parameter in the developability assessment toolkit. The molecule’s ability to maintain stability under low pH stress is paramount for enabling decisions regarding downstream processes such as low pH viral inactivation. The molecule’s low pH behavior is capable of shedding light on potential challenges and opportunities in process development and formulation design.
Identifying molecular candidates with minimal degradation tendencies becomes imperative for steering development toward success. This is where Samsung Biologics’ developability platform excels, particularly during the late discovery stage. Collaborating closely with clients, the platform facilitates a comprehensive understanding of candidate molecules before full-scale development commitments are made. Notably, one of the platform’s key advantages lies in its efficiency: conducting analyses within short timeframes and utilizing minimal material resources. This streamlined approach enables simultaneous evaluation of multiple candidates, fostering informed decision-making and catalyzing transformative advancements in biopharmaceutical development.
Workflow and Characterization
The typical workflow process of the developability assessment tool contains a series of meticulously planned steps to examine the intricate properties of candidate molecules. It begins with the initial screening of the primary sequence, where the molecular blueprint is scrutinized for potential vulnerabilities or degradation hotspots. This critical step sets the stage for subsequent analyses by providing a foundational understanding of the molecule’s inherent characteristics.
Following the primary sequence screening, the focus shifts towards biophysical characterization. The molecular architecture is probed through advanced techniques and instrumentation, analyzing critical insights into its structural integrity, thermal stability, and overall biophysical behavior. This workflow stage offers a comprehensive view of the molecule’s physical attributes, laying the groundwork for informed decision-making.
Stress testing then subjects the molecule to a battery of thermal and chemical stressors to gauge its resilience under harsh environmental conditions. This step provides data on the molecule’s stability profile by simulating real-world scenarios, shedding light on potential degradation pathways and vulnerabilities that may impact its efficacy and safety.
Moreover, the developability assessment process offers flexibility to cater to diverse client needs. Optional characterizations, such as colloidal stability and thermodynamic stability, can be incorporated based on specific requirements or concerns. These additional analyses provide:
- Deeper insights into the molecule’s behavior
- Offering a holistic view that informs formulation strategies
- Process optimization
- Overall development decisions
In essence, the developability assessment tool’s workflow represents a comprehensive journey of exploration and analysis, where each step contributes to a nuanced understanding of candidate molecules. By leveraging a combination of screening, characterization, and stress testing techniques, stakeholders gain invaluable insights that empower them to navigate the complexities of biopharmaceutical development with confidence and clarity.
Solubility Evaluation
Solubility evaluation is critical to the developability assessment process. At the stage of late discovery, material amounts are often limited. However, recognizing the significance of understanding solubility, Samsung Biologics employs a PEG precipitation method to meticulously gauge the relative solubility of candidate molecules. Additionally, if desired, a diverse set of solution conditions can also be evaluated in the assessment. This innovative approach offers a robust framework for comparative analysis, enabling stakeholders to discern subtle variations in relative solubility profiles and identify optimal formulations.
The PEG precipitation method is a powerful tool for screening multiple candidates in parallel, even with limited material availability. By assessing the relative solubility of the molecule(s) of interest, Samsung Biologics equips clients with invaluable data to inform strategic decisions regarding further development. This comprehensive evaluation not only aids in selecting the most promising molecules but can also guide formulation strategies to enhance solubility and stability.
Moreover, the PEG precipitation method aligns seamlessly with Samsung Biologics’ commitment to efficiency and precision. By leveraging this methodology as well as its in-house expertise, stakeholders can expedite the assessment process without compromising accuracy or reliability.
Side-By-Side Molecule Comparison
Conducting side-by-side molecule comparisons is a fundamental strategy in determining if one of the candidates is more developable. This approach facilitates a comprehensive assessment of each molecule’s physical, chemical, and biophysical properties, thereby allowing for the discernment of subtle differences that may impact their suitability for further development. With this knowledge, stakeholders can make informed decisions regarding which candidates hold the greatest promise for advancement. Therefore, side-by-side molecule comparison emerges not only as a means of mitigating risks but also as a strategic approach for optimizing success in biopharmaceutical development, ensuring that resources are allocated efficiently and that development pathways are guided by robust scientific evidence.
Conclusion
In conclusion, the journey from discovery to clinical success in biopharmaceutical development is undeniably challenging. However, one key aspect that can significantly mitigate risks and enhance the probability of success is the implementation of a robust developability assessment tool. Throughout this article, we’ve explored the importance, process, and advantages of such assessments, as seen with Samsung Biologics’ developability assessment tool.
Investing in late discovery/early development activities allows pharmaceutical companies to make informed decisions about which candidates to advance into preclinical and clinical development. By optimizing resource allocation, minimizing development costs, and accelerating the timeline to bring new therapeutics to market, this strategy offers a pathway to success.
Key components of Samsung Biologics’ developability assessment tool include molecular stability, low pH stability, and solubility evaluations. By meticulously analyzing these parameters, stakeholders gain invaluable insights into candidate molecules, empowering them to navigate the complexities of biopharmaceutical development with confidence and clarity.
In essence, by embracing the principles of a robust developability assessment, stakeholders can mitigate risks, optimize resources, and enhance the likelihood of success in biopharmaceutical development.
Publication Details
This article appeared in American Pharmaceutical Review: Vol. 27, No. 4May/June 2024Pages: 46-47
Subscribe to oure-newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!